



Tuberculosis Country Profile 2021 Fiji

Source: Global tuberculosis report 2021. Geneva: World Health Organization

Disclaimer: Tuberculosis country profiles are generated automatically based on data reported by countries and which are held in WHO's global TB database.

Tuberculosis profile: Fiji

Population 2020: 0.9 million

Estimates of TB burden*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	590 (460-750)	66 (51-84)
HIV-positive TB incidence	30 (17-47)	3.3 (1.9-5.2)
HIV-negative TB mortality	52 (45-59)	5.8 (5-6.6)
HIV-positive TB mortality	10 (9-12)	1.1 (0.99-1.3)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2020	73% (57-95)
TB patients facing catastrophic total costs, 2017	40% (33-46)
TB case fatality ratio (estimated mortality/estimated incidence), 2020	11% (8-14)

TB case notifications, 2020

Total new and relapse	431
- % tested with rapid diagnostics at time of diagnosis	31%
- % with known HIV status	>100%
- % pulmonary	61%
- % bacteriologically confirmed [^]	48%
- % children aged 0-14 years	27%
- % women (aged ≥15 years)	29%
- % men (aged ≥15 years)	44%
Total cases notified	437

TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	22	5%
- on antiretroviral therapy	17	77%

Drug-resistant TB care**, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases [^]	100%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases [^]	100%
Laboratory-confirmed cases - MDR/RR-TB ^{^^}	0
Patients started on treatment - MDR/RR-TB ^{^^^}	0
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^{^^}	0
Patients started on treatment - pre-XDR-TB or XDR-TB ^{^^^}	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	0

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	30%	527
Previously treated cases, excluding relapse, registered in 2019	23%	26
HIV-positive TB cases registered in 2019	53%	19
MDR/RR-TB cases started on second-line treatment in 2018	0	
XDR-TB cases started on second-line treatment in 2018	0	

TB preventive treatment, 2020


% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100-100)

TB financing

National TB budget, 2021 (US\$ millions)	1
- Funding source, domestic	46%
- Funding source, international	1.7%
- unfunded	52%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




HIV-negative TB mortality

(Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2020

(Number)




Cases attributable to five risk factors, 2020

(Number)



Total budget

(US\$ millions)



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
 ** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
 ^ Calculated for pulmonary cases only
 ^^ Includes cases with unknown previous TB treatment history
 ^^ Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed